News

The certification was subject to the successful completion of AIFA audit of AMRI’s sterile fill and finish facility in Burlington, MA. This approval specifically applies to laboratories and

The companies will collaborate to advance-to-market an RNAi-based therapy for the treatment of non-muscle invasive bladder cancer. Debiopharm will shoulder full responsibility for the development and commercialization of

MOR103 is implicated in a number of inflammatory and other conditions including rheumatoid arthritis (RA) and multiple sclerosis (MS). The HuCAL-derived, fully human antibody is currently being tested

The agreement makes Partek Genomics Suite available through Life Technologies as a featured solution for analyzing data generated by Life Technologies’ next-generation sequencing (NGS) devices. Partek Genomics Suite

According to American Regent, potassium phosphates injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, belonging to lot number 48 is being

Bayer had initiated patient enrolment for a randomised, double-blind, placebo-controlled Phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with

The new investigational regimen, termed as 572-Trii, will combine the investigational integrase inhibitor S/GSK1349572 (‘572) and ViiV Healthcare’s combination nucleoside reverse transcriptase inhibitor (NRTI) Kivexa/Epzicom (ABC/3TC). The multi-centre,

Subsequently, Galapagos has regained worldwide rights for all assets developed in its strategic alliances with Merck & Co, through an affiliate. Merck will make a payment of EUR12m

The $300m transaction is expected to increase profitability of the brand for BLS which had previously been the exclusive distributor in the US, and expands BLS’ geographic rights